The peritoneum is impaired by exposure to biocompatible dialysis solutions. Because icodextrin peritoneal dialysis fluid (PDF) is made from cornstarch, a possibility that it induces intraperitoneal inflammation has been reported. In the present study, patients on glucose PDF were switched to icodextrin PDF and then switched back to glucose PDF. Icodextrin PDF-induced intraperitoneal inflammation was investigated based on changes in peritoneal permeability and inflammatory reactions.
⋄ Patients and Methods
The subjects were 7 stable peritoneal dialysis patients (4 men, 3 women), with a mean age of 59.1 ± 3.8 years (range: 55.2 - 64.6 years). The mean duration of peritoneal dialysis was 58.3 ± 27.4 months (range: 34.3 - 97.7 months), and the cause of end-stage renal disease was chronic glomerulonephritis in all patients.
For the overnight dwell, glucose PDF was changed to icodextrin PDF, and the patients returned to glucose PDF 30 months later. To evaluate peritoneal permeability, a peritoneal equilibrium test (PET) was performed, and dialysate-to-plasma (D/P) ratios of creatinine (Cr), β2-microglobulin (β2M), albumin, immunoglobulin G (IgG), and α2-macroglobulin (α2M) were measured in the overnight dialysate and serum. As markers of inflammation and fibrinolysis or coagulation, interleukin-6 (IL-6) and fibrinogen degradation products (FDPs) were measured in overnight effluent. The evaluations were made every 6 months for 36 months.
⋄ Results
A significant elevation in FDP levels was detected in overnight effluent 6 months after the switch to icodextrin PDF, and IL-6 levels tended to increase. The D/P ratios of Cr, β2M, and albumin were also significantly increased, and the D/P ratios of IgG and α2M tended to increase. The D/P ratio of Cr as measured by PET was slightly increased, but the elevation was not significant. In 5 patients, after icodextrin PDF was switched back to glucose PDF at 30 months, the D/P ratios of Cr, β2M, albumin, IgG, and α2M in overnight effluent were significantly reduced. The FDP levels decreased slightly in those patients. In the remaining 2 patients, the D/P ratios of Cr on PET and of Cr, β2M, albumin, IgG, and α2M in overnight effluent, and the FDP and IL-6 levels in overnight effluent were markedly elevated after the switching from glucose to icodextrin PDF, and they remained high after the switch back to glucose PDF. One of these 2 patients developed pre-EPS and was treated with prednisolone and concomitant hemodialysis. The other was switched from peritoneal dialysis to hemodialysis.
⋄ Conclusions
Icodextrin dialysis solution may induce an inflammatory reaction in the peritoneum. Further investigation is necessary for the long-term use of icodextrin PDF.
WilliamsJDCraigKJvon RuhlandCTopleyNWilliamsGT on behalf of the Biopsy Registry Study Group. The natural course of peritoneal membrane biology during peritoneal dialysis. Kidney Int Suppl2003; 88:S43–9.
2.
VardhanAZweersMMGokalRKredietRT. A solutions portfolio approach in peritoneal dialysis. Kidney Int Suppl2003; 88:S114–23.
3.
ParikovaAZweersMMStruijkDGKredietRT. Peritoneal effluent markers of inflammation in patients treated with icodextrin-based and glucose-based dialysis solutions. Adv Perit Dial2003; 19:186–90.
4.
MinamiSHoraKKamijoYHiguchiM.Relationship between effluent levels of β2-microglobulin and peritoneal injury markers in 7.5% icodextrin-based peritoneal dialysis solution. Ther Apher Dial2007; 11:296–300.
5.
MartikainenTATeppoAMGrönhagen–RiskaCEkstrandAV. Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane?Perit Dial Int2005; 25:453–60.
6.
GotloibLWajsbrotVShostakA.Mesothelial dysplastic changes and lipid peroxidation induced by 7.5% icodextrin. Nephron2002; 92:142–55.
7.
HaHYuMRChoiHNChaMKKangHSKimMH. Effects of conventional and new peritoneal dialysis solutions on human peritoneal mesothelial cell viability and proliferation. Perit Dial Int2000; 20(Suppl 5):S10–18.
8.
AlsopRM. History, chemical, and pharmaceutical development of icodextrin. Perit Dial Int1994; 14:S5–12.
9.
MartisLPatelMGiertychJMongovenJTaminneMPerrierMA. Aseptic peritonitis due to peptidoglycan contamination of pharmacopoeia standard dialysis solution. Lancet2005; 365:588–94.
10.
PovlsenJVIvarsenPJørgensenKAMadsenS.Exposure to the peptidoglycan contaminant in icodextrin may cause sensitization of the patient maintained on peritoneal dialysis. Perit Dial Int2003; 23:509–10.
11.
TouréFLavaudSMohajerMLavaudFCanivetENguyenP. Icodextrin-induced peritonitis: study of five cases and comparison with bacterial peritonitis. Kidney Int2004; 65:654–60.
12.
DaviesSJBrownEAFrandsenNERodriguesASRodriguez-CarmonaAVychytilA. Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int2005; 67:1609–15.
13.
BajoMASelgasRCastroMAdel PesoGDiazCSánchez–TomeroJA. Icodextrin effluent leads to a greater proliferation than glucose effluent of human mesothelial cells studied ex vivo. Perit Dial Int2000; 20:742–7.
14.
KoningsCJSchalkwijkCGvan der SandeFMLeunissenKMKoomanJP. Influence of icodextrin on plasma and dialysate levels of Nɛ-(carboxymethyl)lysine and Nɛ-(carboxyethyl)lysine. Perit Dial Int2005; 25:591–5.
15.
MoriishiMKawanishiHWatanabeHTsuchiyaS.Effect of icodextrin-based peritoneal dialysis solution on peritoneal membrane. Adv Perit Dial2005; 21:21–4.
16.
MoriishiMKawanishiHWatanabeHTsuchiyaS.Correlation between peritoneal permeability and ultrafiltration volume with icodextrin-based peritoneal dialysis solution. Adv Perit Dial2004; 20:166–9.
17.
MoriishiMKawanishiHTsuchiyaS.Impact on peritoneal membrane of use of icodextrin-based dialysis solution in peritoneal dialysis patients. Adv Perit Dial2006; 22:24–8.
